Cefaclor revisited

Clinical Therapeutics

Volumn 22, Issue 2, 2000, Pages 154-166

  Meyers, Burt R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic therapy; Cefaclor; Cephalosporins; Respiratory tract infections

Indexed keywords

CEFACLOR;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; RESPIRATORY TRACT INFECTION; REVIEW; SUSTAINED DRUG RELEASE;

EID: 0034100573     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)88477-5     Document Type: Article

References (45)

1. 1. Cole P. Pharmacologic and clinical comparison of cefaclor in immediate-release capsule and extended-release tablet forms. Clin Ther. 1997;19:617-625.
2. 2. Novelli A. Molecular factors responsible for the clinical efficacy of cefaclor. In: Cole P, ed. Current Issues in the Management of Respiratory Tract Infections: A Focus on Cefaclor. London: The Royal Society of Medicine Press Ltd; 1998: 27-37.
3. 3. Meyers BR, Hirschman SZ. Antimicrobial activity in vitro of cefaclor, a new oral cephalosporin. J Clin Pharmacol. 1978; 18:85-90.
4. 4. Meyers BR, Hirschman SZ, Wormser G, et al. Pharmacologic studies with cefaclor, a new oral cephalosporin. J Clin Pharmacol. 1978;18:174-179.
5. 5. Maniatis T, Castellano M. Comparative evaluation of cefaclor versus amoxicillin/ clavulanate potassium in the treatment of bacterial bronchitis. Curr Ther Res. 1990; 48:308-312.
6. 6. Frampton JE, Brogden RN, Langtry HD, Buckley MM. Cefpodoxime proxetil: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1992;44:889-917.
7. 7. Kammer RB, Ress R. Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections. Diagn Microbiol Infect Dis. 1991;14:101-105.
8. 8. Pelletier LI Jr. Review of the experience with cefprozil for the treatment of lower respiratory tract infections. Clin Infect Dis. 1992;14(Suppl 2):S238-S243.
9. 9. Dere WH, Farlow D, Therasse DG, Ruoff GE. Loracarbef (LY163892) versus cefaclor in the treatment of acute bacterial bronchitis. Clin Ther. 1992;14:41-53.
10. 10. Wettengel R, Vetter N, Waardenburg FA. Clarithromycin versus cefaclor for the treatment of mild-to-moderate acute bacterial bronchitis. J Antimicrob Chemother. 1993;31:963-972.
11. 11. Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am J Med. 1991;91(Suppl 3A):31S-35S.
12. 12. Quenzer RW, Davi RL, Neidhart MM. Prospective randomized study comparing the efficacy and safety of ciprofloxacin with cefaclor in the treatment of patients with purulent bronchitis. Diagn Microbiol Infect Dis. 1990;13:143-148.
13. 13. Gotfried MH, Ellison WT. Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis. Am J Med. 1992;92 (Suppl 4A):108S-113S.
14. 14. Derriennic M, Voi M, Thoren LM, et al. Cefaclor AF in the treatment of streptococcal pharyngitis/tonsillitis. Postgrad Med J. 1992;68(Suppl 3):S43-S48.
15. 15. Grossman RF. Cefaclor AF versus cefaclor in acute exacerbations of chronic bronchitis. Postgrad Med J. 1992;68(Suppl 3): S30-S37.
16. 16. Alanis A, Longest KA, Senetar JE, Dere WH. A multicentre trial of cefaclor advanced formulation versus cefaclor in the treatment of acute bronchitis. Postgrad Med J. 1992;68(Suppl 3):S24-S29.
17. 17. Cole P. Management of chronic respiratory infections: Today and tomorrow. In: Cole P, ed. Current Issues in the Management of Respiratory Tract Infections: A Focus on Cefaclor. London: The Royal Society of Medicine Press Ltd; 1998:1-11.
18. 18. Sides GD, Franson TR, DeSante KA, Black HR. A comprehensive review of the clinical pharmacology and pharmacokinetics of cefaclor. Clin Ther. 1988;11l(Suppl A):5-19.
19. 19. Thornsberry C. Cefaclor AF: Correlation of microbiology and clinical outcome. Postgrad Med J. 1992;68(Suppl 3):S10-S16.
20. 20. Physicians' Desk Reference®. 53rd ed. Montvale, NJ: Medical Economics Company; 1999:946.
21. 21. Wilson R. Antibiotic management of patients with bronchial infections. In: Cole P, ed. Cefaclor: Into the Next Decade. London: The Royal Society of Medicine Services; 1992:33-40.
22. 22. Pichichero ME, Margolis PA. A comparison of cephalosporins and penicillins in the treatment of Group A beta-hemolytic streptococcal pharyngitis: A meta-analysis supporting the concept of microbial copathogenicity. Pediatr Infect Dis. 1991;10:275-281.
23. 23. Reed BD, Huck W, Zazove P. Treatment of β-hemolytic streptococcal pharyngitis with cefaclor or penicillin. J Fam Pract. 1991;32:138-144.
24. 24. Klugman KP, Feldman C. The clinical relevance of antibiotic resistance in the management of pneumococcal pneumonia. Infect Dis Clin Pract. 1998;7:180-184.
25. 25. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40: 1208-1213.
26. 26. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333:474-480.
27. 27. McCabe R, Rumans L, Perrotta R, Mogabgab W. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis. J Chemother. 1993;5:124-132.
28. 28. Phillips H, Van Hook CJ, Butler T, Todd WM. A comparison of cefpodoxime proxetil and cefaclor in the treatment of acute exacerbation of COPD in adults. Chest. 1993;104:1387-1392.
29. 29. Yangco BG, Lowe J, Nolen TM, et al. A multicenter trial comparing the efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults. Clin Ther. 1990;12:440-446.
30. 30. Drehobl M, Bianchi P, Keyserling CH, et al. Comparison of cefdinir and cefaclor in treatment of community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41:1579-1583.
31. 31. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Inject Dix. 1991;10:872-877.
32. 32. Donowitz GR, Brandon ML, Salisbury JP, et al. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: A randomized, double-masked, comparative, multicenter study. Clin Ther. 1997;19:936-953.
33. 33. Hendershot EF. Fluoroquinolones. Dis Clin North Am. 1995;9:715-730.
34. 34. Grouhi M, Hummel D, Roifman CM. Anaphylactic reaction to oral cefaclor in a child. Pediatrics. 1999;103:e50.
35. 35. Vial T, Pont J, Pham E, et al. Cefaclor-associated serum sickness-like disease: Eight cases and review of the literature. Ann Pharmacother. 1992;26:910-914.
36. 36. Hebert AA, Sigman ES, Levy ML. Serum sickness-like reactions from cefaclor in children. J Am Acad Dermatol. 1991; 25:805-808.
37. 37. Stotka JL, Senetar JE, Therasse DG, Dere WH. Comprehensive safety profile of cefaclor AF in respiratory, urinary tract, and skin infections. Postgrad Med J. 1992;68 (Suppl 3):S73-S78.
38. 38. Ciprox® [package insert]. West Haven, Conn: Bayer Pharmaceuticals; 1997.
39. 39. Floxin® [package insert], Raritan, NJ: Ortho-McNeil Pharmaceutical Corporation; 1997.
40. 40. Biaxin® [package insert]. North Chicago, Ill: Abbott Laboratories; 1997.
41. 2-receptor antagonists. Postgrad Med J. 1992;68 (Suppl 3):S3-S9.
42. 42. Cole P. Clinical comparison of immediate-release cefaclor with a new extended-release formulation of cefaclor in outpatient infections. Curr Ther Res. 1997;58: 816-827.
43. 43. Smucny JJ, Becker LA, Glazier RH, McIsaac W. Are antibiotics effective treatment for acute bronchitis? A meta-analysis. J Fam Pract. 1998;47:453-460.
44. 44. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.
45. 45. Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J. 1992;68 (Suppl 3):S58-S59.